Bernard Marini - Podcast Details

Shows

WolverHeme Happy HourCSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically ExaminedThis is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/ 2025-05-051h 10

WolverHeme Happy HourDex and the Cytokine City: Managing CRS with BispecificsIn this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!Inspired by this recent paper:https://www.nature.com/articles/s41408-025-01222-y 2025-04-0759 min

WolverHeme Happy HourLFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AMLIn this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in AML? Tune in to find out!2025-03-111h 04

WolverHeme Happy HourEpisode 32: Navigating a BlinatumoMAD WorldIn this episode, Anthony and Bernie are joined by two special guests to discuss recent updates to the use of blinatumomab in both adult and pediatric acute lymphoblastic leukemia (ALL), including the results of the AALL1731 trial and the full publication of ECOG1910. Julia Brown, PharmD, a Pediatric Hematology/Oncology Clinical Pharmacist and Lydia Benitez, an Adult Outpatient Leukemia Clinical Pharmacist bring their unique perspectives and expertise on the proper incorporation of blinatumomab into ALL care, as well as some of the major practical nuances that will be helpful to providers across the globe! Finally...2025-01-211h 06

WolverHeme Happy HourThe Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple MyelomaAQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion. Note: L'aquila is Italian for eagle! AQUILA: Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Epub ahead of print. PMID: 39652675. 2025-01-1549 min

WolverHeme Happy HourPour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma UpdatesIn this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen! Some selected abstracts: EA4151: https://ash.confex.com/ash/2024/webprogram/Paper212973.html Triangle Updates: https://ash.confex.com/ash/2024/webprogram/Paper200735.html , https://ash.confex.com/ash/2024/webprogram/Paper201441.html EA4181: https://ash.confex.com/ash/2024/webprogram/Paper194641.html ENRICH: https://ash.confex.com/ash/2024/webprogram/Paper199710.html inMIND: https://ash.confex.com/ash/2024/webprogram/Paper212970.html POLARIX Long-Term...2024-12-241h 03

WolverHeme Happy HourA Bunch of ASHholes Discuss Myeloma AbstractsIn this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out! 2024-11-1656 min

WolverHeme Happy HourCast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin LymphomaIn this episode, Bernie and Anthony are joined by two special guest expert hematologists: Dr. David Russler-Germain Dr. Tycel Phillips We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired? Stay tuned to find out!2024-11-0848 min

WolverHeme Happy HourEpisode 27: Mantle Cell Masterclass with Tycel PhillipsIn this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL. TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/ Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/2024-10-101h 01

OrganissimoAxel Ruoff : l'intégrale d'orgue (1)Après vous avoir présenté des extraits de l'intégrale des œuvres d'orgue de Bach par Bernard Focroulle, et ensuite l'intégrale de Max Reger par Roberto Marini, je vous invite aujourd'hui à explorer un compositeur contemporain : Axel Ruoff.Né le 24 mars 1957 à Stuttgart, Axel Ruoff est un compositeur dont l'œuvre pour orgue est l'une des contributions les plus significatives à la littérature de cet instrument depuis Messiaen. Sa musique s'inscrit dans la lignée des grands compositeurs français tels que Langlais, Dupré, et Guillou. Comme Messiaen, Ruoff puise son inspiration dans les sources religieuses, trouvant dans les récits bibl...2024-09-1326 min

WolverHeme Happy HourHouston, we don't have a problem... with APOLLOIn this episode, Anthony and Bernie discuss the recently reported APOLLO trial in high-risk APL and debate whether this should represent the new standard of care in this population. We also review key practical considerations for the treatment of APL patients, including side effect management and treatment of APL in unique clinical scenarios. APOLLO: https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html 2024-08-2858 min

Sounds of BlueSOB 458 - 4-hour Luther Kent TributeArtist Song Album Label NotesLuther Kent 4-Hour Tribute for Big Luther Kent Various Recordings Various Labels Luther Kent R.I.P. at 76Kinks Gallon of Gas - ID Low Budget - 1979 & 45 RPM Single Arista Records 2023 Gasoline & Oil ID - Luther Kent 99 Women by Luther Kent & Jack Calmes w/Charlie Brent, Allyn Robinson, Jack Calmes + Deep In the Heart - 2003 - Antone's Austin, TX Louisiana Red Hot Records Luther Kent R.I.P. at 76 - Luther Kent I Got News for You by Roy Alfred w/Lou Marini, Jon Smith, Tommy Young, Charlie Brent + Live From the Gypsy...2024-08-194h 06

Sounds of BlueSOB 448: Features: More David Sanborn, Derek Trucks, Grant Green & Chuck Rainey,Artist Song Album Label Notes- Bernard Herrmann & Rod Serling + Rod Serling Opening Monologue - Season One w/Bernard Herrmann's "Dream Theme" 40th Anniversary Twilight Zone - 1st Season - 1959 Silva Treasury - 4CD's Brand New SOB ID for 2024- David Sanborn, Clapton & M. Kamen Riggs by David Sanborn, Eric Clapton & Kamen w/David Sanborn, Clapton & Kamen + Lethal Weapon 2 - 1989 Warner Bros Remembering David Sanborn- Randy Crawford w/Sanborn & Clapton Knockin' On Heaven's Door by Bob Dylan w/Sanborn & Clapton + Lethal Weapon 2 - 1989 Warner Bros Remembering David Sanborn- Grant Green Sunday Mornin' by Grant Green w/Ben Tucker...2024-06-304h 04

WolverHeme Happy HourFrom Ancient Remedies to Modern Miracles: The Evolution of APL TreatmentIn this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024! How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today? And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out! 2024-06-1358 min

WolverHeme Happy HourEpisode 24: Myeloma Madness with the Myeloma ManIn this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma. 2024-04-1758 min

WolverHeme Happy HourAnthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussionIn this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL! Abstracts discussed: https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions) https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R...2024-01-2557 min

WolverHeme Happy HourLymphOMG: Pouring Over Lymphoma Abstracts from ASHOMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion! Abstracts Discussed! SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883...2023-12-291h 12

WolverHeme Happy HourAMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven AlchemyIn this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial! Abstracts: FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html Revumenib Late Breaking Abstract: https://ash.confex.com/ash/2023/webprogram/Paper192042.html JNJ617 Menin Inhibitor Data: https://ash.confex.com/ash/2023/webprogram/Paper172422.html SAVE Trial (Revumenib + PO Dec/ven): https://ash.confex.com/ash/2023/webprogram/Paper182337.html Dec/Ven vs. 3+7 Randomized Phase II: https://ash.confex.com/ash/2023/webprogram/Paper181347.html NCRI AML18 RCT: https://ash.confex.com/ash/2023/webprogram/Paper185956.html ...2023-12-1941 min

WolverHeme Happy HourASH Pregaming - Myeloma Madness with Manni and Papa HemeIn this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will any of these change practice? Listen to find out! Abstracts Discussed: https://ash.confex.com/ash/2023/webprogram/Paper188547.html https://ash.confex.com/ash/2023/webprogram/Paper181765.html https://ash.confex.com/ash/2023/webprogram/Paper177954.html https://ash.confex.com/ash/2023/webprogram/Paper191911.html https://ash.confex.com/ash/2023/webprogram/Paper179866.html https://ash...2023-12-0152 min

WolverHeme Happy HourAML Maintenance Part 2: a metaMORPHOsis?In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice! Sorafenib observational study: https://pubmed.ncbi.nlm.nih.gov/30809038/ SORMAIN (sorafenib): https://pubmed.ncbi.nlm.nih.gov/32673171/ Chinese Sorafenib Phase III: https://pubmed.ncbi.nlm.nih.gov/32791048/ RADIUS (midostaurin): https://pubmed.ncbi.nlm.nih.gov/33288862/ AMLSG 16-10 (midostaurin): https://pubmed.ncbi.nlm.nih.gov/30563875/ MORPHO (EHA abstract): https://library.ehaweb.org/eha/2023/eha2023-congress/391322/faculty.presenters.bmt-ctn.1506.28...2023-11-0854 min

WolverHeme Happy HourAML Maintenance Part 1: Set Your QUAZARs to StunIn the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study. Key References: QUAZAR AML-001: https://pubmed.ncbi.nlm.nih.gov/33369355/ QUAZAR Letter to the Editor: https://pubmed.ncbi.nlm.nih.gov/33789022/ ASH Abstract Data on impact of # of Consolidation Cycles: https://ash.confex.com/ash/2020/webprogram/Paper138498.html Hovon 97 (Azacitidine SQ maintenance): https://pubmed.ncbi.nlm.nih.gov/30630862/ Mayer, et al. NEJM. 1994...2023-10-2551 min

WolverHeme Happy HourEpisode 17: The Hemophilia Eras TourIn this episode, we are joined by classical hematology experts, Madeleine Ochs, PharmD, BCOP and Justin Arnall, PharmD, BCOP, to teach us hemophilia 101! In this T-Swift themed, episode, we discuss the history of hemophilia treatment (through the "eras") and how new agents may change the management of hemophilia patients. 2023-08-231h 39

WolverHeme Happy HourCommon Sense Oncology: Outcomes That MatterIn this episode, Anthony and Bernie chat with Chris Booth, MD, and Aaron "Papa Heme" Goodman, MD, to talk about the Common Sense Oncology movement! Join the Common Sense Oncology movement at this link (it's free!): https://commonsenseoncology.org/ Lancet Oncol paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00319-4/fulltext 2023-08-0137 min

WolverHeme Happy HourAll too well: the reality of leukemia treatmentIn this episode, Anthony, Bernie, and Lydia are joined by a former patient, Madeline B, to talk about her ALL treatment journey. Drawing inspiration from Taylor Swift's upcoming concert and heartfelt ballad ("All Too Well"), this episode tackles some of the unique challenges, emotions, and considerations that come with helping adolescents and young adults (AYA) with treatment for acute leukemia. This is a must-listen for anyone taking care of AYA patients! 2023-06-0849 min

WolverHeme Happy HourEpisode 14: A Quantum Leap in AML Treatment? Dissecting Quizartinib Data with Dr. Dale BixbyIn this episode, Anthony and Bernie are joined once again by special guest and hematology expert, Dr. Dale Bixby, to discuss the recent publication of the QUANTUM-First study of quizartinib in newly diagnosed AML. Should this study change practice in FLT3-ITD+ AML? Have we made a "Quantum Leap" in the treatment of these patients? Listen for a fun-filled discussion of the data! Notable References: QUANTUM-First Study: https://pubmed.ncbi.nlm.nih.gov/37116523/ WolverHeme Episode 8 (Pulling the Goalie on FLT3 Inhibitor Use in AML): https://podcasters.spotify.com/pod/show/wolverheme/episodes/Episode-8...2023-05-091h 10

WolverHeme Happy HourEpisode 13: You get blinatumomab! You get blinatumomab!Blinatumomab - it's Oprah's new favorite drug! On this episode, Anthony and Bernie are joined by special guests Dr. Lydia Benitez and Dr. Patrick Burke to discuss the ECOG1910 trial of blinatumomab in adult ALL. Is this trial practice changing? Listen and find out! ECOG1910 Late-Breaking Abstract: https://ash.confex.com/ash/2022/webprogram/Paper171751.html 2023-02-241h 08

WolverHeme Happy HourEpisode 12: Tinder for T Cells - Bispecifics in DLBCLIn this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain. Relevant Articles: Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/ Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/ Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/ Mosunetuzumab...2023-02-0858 min

WolverHeme Happy HourEpisode 11: "Olu the Drunk Snowman" - IDH inhibitors in R/R AML with Dr. Jill LykonIn this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib? Olutasidenib Phase I - Watts, et al. Lancet. 2023: https://pubmed.ncbi.nlm.nih.gov/36370742/ Olutasidenib Phase II ASH Abstract: https://ash.confex.com/ash/2022/webprogram/Paper167330.html Ivosidenib Phase I escalation/expansion - Dinardo, et al. NEJM. 2018: https://p...2023-01-2152 min

WolverHeme Happy HourEpisode 10: ASH Recap Part 2 - Papa Heme + WolverHemeIn this episode, we are joined by the legendary hematologist and rock star - Dr. Aaron Goodman - aka "Papa Heme"! We discuss which ASH abstracts might be practice changing and which simply don't make the cut. Stay tuned for an entertaining and very educational episode! 2022-12-211h 13

WolverHeme Happy HourEpisode 9: ASH Recap Part 1 - Dauno-Double TroubleIn this episode, Anthony and Bernie begin to recap some interesting studies presented at ASH, starting with a discussion the results of the "Dauno-Double" Trial. Should it change practice? Dauno-Double Trial: https://ash.confex.com/ash/2022/webprogram/Paper157126.html Dr. Todd Lee breaking down the non-inferiority numbers: https://twitter.com/DrToddLee/status/1600662377250586627?s=20&t=RdIhJJpMG-G_oPUSH2u2mw 2022-12-1440 min

WolverHeme Happy HourEpisode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale BixbyIn this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views! REFERENCES Schlenk and Dohner (Impact of AML prognostic markers)l: https://pubmed.ncbi.nlm.nih.gov/19468271/ RATIFY Trial...2022-11-231h 22

WolverHeme Happy HourEpisode (3+)7: Straight Outta Roswell - OG AML DataFinally back from a much needed vacation, in this episode, Anthony and Bernie discuss some of the "OG" data and pharmacology behind key AML therapies. 2022-10-0747 min

Ta de ClinicagemEpisódio 157: Droga Vasoativa - 4 Clinicagens🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨 🔴 Junte-se aos mais de 1.000 assinantes. Assine o Guia, ganhe tempo e atualize-se sem esforço. 🟠 Um serviço de revisão e atualização continuados em clínica médica. A informação que você precisa, do jeito que você prefere. 📚 Confira agora mesmo a edição aberta do Guia TdC sobre a Nova Diretriz de Hiperglicemia no Paciente Internado: https://www.tadeclinicagem.com.br/guia/edition/revisao-2 Pedro, Kaue e Victor Delia se encontram para falar 4 clin...2022-10-0647 min

WolverHeme Happy HourEpisode 6: Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the AsparaginaseIn this episode, Bernie and Anthony do an in-depth dive into the pharmacology, toxicity management, and clinical conundrums with asparaginase therapy, including how and when to monitor asparaginase activity levels (per Papa Heme request!). For those who don't know (and maybe aren't as nerdy as we are), the title is a reference to the 1964 film Dr. Strangelove!2022-07-211h 15

WolverHeme Happy HourEpisode 5: IDH Inhibitors in AML: not so AGILEIn this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML, based on the results of the AGILE study: https://www.nejm.org/doi/full/10.1056/NEJMoa2117344 2022-06-041h 24

WolverHeme Happy HourEpisode 4: All Aboard the Oncology StewardSHIPIn this episode, Bernie Marini and Anthony Perissinotti are joined by two special guest hematology experts - Lydia Benitez, PharmD, BCOP, and Madeleine Ochs, PharmD, BCOP. Maddy and Lydia help us dive into the topic of Oncology Stewardship, including how we can incorporate Oncology Stewardship into practice to improve outcomes for patients. Learn more about Oncology Stewardship in AML patients in our hot off the press paper in Annals of Hematology, written by Maddy (first author), Lydia (senior author), and the rest of our leukemia team: https://link.springer.com/article/10.1007/s00277-022-04872-1 2022-05-2755 min

WolverHeme Happy HourEpisode 3.2: Ranting About Rituximab in Acute Lymphoblastic LeukemiaIn part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also discuss the previously published GRAALL study that evaluated rituximab in ALL (Maury, et al. NEJM, 2016, https://pubmed.ncbi.nlm.nih.gov/27626518/), and what we can conclude from the literature to date. The data surprises us, and makes us question our own practices!2022-04-2350 min

WolverHeme Happy HourEpisode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM BackboneIn part one of a two-part episode, Bernie Marini and Anthony Perissinotti take a journey through the history of acute lymphoblastic leukemia treatment throughout the decades and explain how we got to our current standard of care treatment of ALL patients. In part 2 we tackle the UKALL14 study evaluating the addition of rituximab to acute lymphoblastic leukemia therapy. Some important historical articles that we reference: Nitrogen mustard therapy: https://pubmed.ncbi.nlm.nih.gov/20997191/ Methotrexate/Aminopterin: https://www.nejm.org/doi/full/10.1056/nejm194806032382301 Vincristine: https://pubmed.ncbi.nlm.nih.gov/13627916/ and https://pubmed.ncbi.nlm.nih...2022-04-2346 min

WolverHeme Happy HourEpisode 2: We Don't Talk About RylazeBernie Marini and Anthony Perissinotti discuss asparaginase, the data (or lack thereof) behind the FDA approval of Rylaze (Erwinia asparaginase), and concerning trends regarding switches between asparaginase products in clinical practice! 2022-03-1844 min

WolverHeme Happy HourEpisode 1: Surrogate Endpoints in AMLBernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML: Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2022 Mar 10;40(8):847-854. PMID: 34890212.2022-03-1125 min

Plenary Session - inactive due to federal service4.32 Oral Azacitidine for AML and Nelarabine for T-ALL with Dr. Bernard MariniWe're back with a hematology/oncology heavy episode! We talk about oral azacitidine for acute myeloid leukemia (AML) and nelarabine for T-cell acute lymphoblastic leukemia (T-ALL) with Dr. Bernie Marini, a Clinical Pharmacist Specialist in Hematology and Associate Professor at University of Michigan Medicine. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew 2021-12-031h 05

Plenary Session - inactive due to federal service3.60 Drugs for Acute Lymphoblastic Leukemia with Dr. Bernard MariniToday we bring back popular guest Dr. Bernie Marini, a Clinical Pharmacist Specialist in Hematology at University of Michigan Medicine, to discuss treatment of Acute Lymphoblastic Leukemia (ALL). Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew 2021-03-311h 22

Silence, On JazzJazz, sans en avoir l'airComme le latin irrigue la langue française, le jazz s’immisce dans toute la musique moderne, au détour d’un instrument, d’une partition ou d’une tradition. Thomas Dutronc, dont l’oreille s’intéresse à tous les styles et toutes les époques, nous montre comment le jazz est bien souvent là, sans forcément en avoir l’air… Playlist : Miss Annabel Lee - Django Clopin, clopant - Henri Salvador Le Blues du Blanc - Eddy Mitchell For Me Formidable - Aznavour La Femme des uns sous le corps des autres - Gainsbourg Quand j’serai KO - Souchon J’aime les filles - Dutr...2021-01-1348 min

Plenary Session - inactive due to federal service3.27 All Recent Acute Myeloid Leukemia Drugs with Dr. Bernard MariniOn today's episode we discuss all the new drugs for acute myeloid leukemia with Dr. Bernie Marini, a Clinical Pharmacist Specialist in Hematology at University of Michigan Medicine. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew 2020-12-1756 min